Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00731211 · ClinicalTrials.gov registry record · Phase 2
Pazopanib in Previously Treated Patients With Metastatic Renal Cell Carcinoma
A Phase 2 study, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 2
- Development phase
- 57
- Enrollment target
NCT00731211 is a Phase 2 study that has completed, run by SCRI Development Innovations. The registered enrollment target is 57 participants.
The verdict
NCT00731211, a Phase 2 study, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 57 participants
- Enrollment target
Study Summary
This is a Phase II, non-randomized, open-label, single-arm study in patients with metastatic renal cell carcinoma who have received one prior targeted therapy with either sunitinib or bevacizumab. The planned enrollment for this study is 60 patients.
Interventions
- DRUG Pazopanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2008-09 |
| Est. Completion | 2012-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00731211
The ClinicalTrials.gov registry entry for NCT00731211 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pazopanib is the first listed.
NCT00731211 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00731211 about?
NCT00731211 is a clinical study titled "Pazopanib in Previously Treated Patients With Metastatic Renal Cell Carcinoma". This is a Phase II, non-randomized, open-label, single-arm study in patients with metastatic renal cell carcinoma who have received one prior targeted therapy with either sunitinib or bevacizumab. The planned enrollment for this study is 60 patients.
What is the current status of trial NCT00731211?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 57 participants. The study started on 2008-09. Estimated completion is 2012-09.
What interventions are being tested in trial NCT00731211?
The interventions under investigation include: Pazopanib (DRUG).
Who is sponsoring clinical trial NCT00731211?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.